Anti-CTLA-4 therapy for malignant mesothelioma

• Published in: Immunotherapy Vol. 9; no. 3; pp. 273 - 280
• Main Authors: Guazzelli, Alice, Bakker, Emyr, Krstic-Demonacos, Marija, Lisanti, Michael P, Sotgia, Federica, Mutti, Luciano
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.03.2017
• Subjects: Animals; anti-CLTA-4; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Antineoplastic Agents - therapeutic use; B7-H1 Antigen - immunology; B7-H1 Antigen - metabolism; Biomarkers; Cancer therapies; Chemotherapy; Clinical trials; Clinical Trials as Topic; CTLA-4 Antigen - immunology; CTLA-4 Antigen - metabolism; CTLA-4 protein; Humans; Immune checkpoint inhibitors; Immune system; Immunoglobulins; Immunotherapy; Immunotherapy - methods; Ligands; Lung Neoplasms - immunology; Lung Neoplasms - therapy; Lymphocyte Activation; Lymphocytes; malignant mesothelioma; Medical prognosis; Melanoma; Mesothelioma; Mesothelioma - immunology; Mesothelioma - therapy; Mesothelioma, Malignant; Metastases; Neoplasm Metastasis; PD-1 protein; PD-L1 protein; Programmed Cell Death 1 Receptor - immunology; Programmed Cell Death 1 Receptor - metabolism; Solid tumors; Studies; T-Lymphocytes - immunology; Treatment Outcome; Tumors; United States > US; Chicago Illinois; malignant mesothelioma; immunotherapy; anti-CLTA-4

Immunotherapy is an emerging therapeutic strategy with a promising clinical outcome in some solid tumors, particularly metastatic melanoma. One approach to immunotherapy is immune checkpoint inhibitors, such as blockage of CTLA-4 and PD-1/PD-L1. This special report aims to describe the state of clin...